Whilst focused ultrasound-mediated delivery of OLA was recently reported to confer radiosensitization in a diffuse midline glioma model [27], and nanoparticles encapsulated with the PARP inhibitor talazoparib was shown to induce tumor regression and reduce leptomeningeal spread in a preclinical metastatic model of medulloblastoma [28], there have been no reported studies assessing localized OLA delivery in a cortical high grade glioma model. This evidence concerns the gene PARP1 and neoplasm.